Protalix BioTherapeutics, Inc. (PLX): Cash & Equivalents
$14.68M
As of 2025-12-31
$27.42M
As of 2026-06-30
-5.0%
3-year compound annual growth
-4.3%
5-year compound annual growth
-15.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.68M | -25.7% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $19.76M | -16.4% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $23.63M | +38.1% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $17.11M | -56.1% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $38.98M | +113.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $18.27M | +2.7% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $17.79M | -52.9% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $37.81M | -26.1% | 2021-03-30, Balance as of period end |
| 2017-12-31 | $51.16M | -19.1% | 2020-03-12, Balance as of period end |
| 2016-12-31 | $63.28M | -17.1% | 2019-03-18, Balance as of period end |
| 2015-12-31 | $76.37M | +39.5% | 2018-03-06, Balance as of period end |
| 2014-12-31 | $54.77M | -36.6% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $86.40M | +66.0% | 2016-03-08, Balance as of period end |
| 2012-12-31 | $52.03M | +92.7% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $27.00M | -24.8% | 2014-03-13, Balance as of period end |
| 2010-12-31 | $35.90M | -55.8% | 2013-02-28, Balance as of period end |
| 2009-12-31 | $81.27M | n/a | 2012-02-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
Compare PLX, IVVD, FENC, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗